Patrick Soon-Shiong & ImmunityBio
6 shared events · Importance 5 · Last updated Jun 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Patrick Soon-Shiong is the founder, executive chairman, and global chief scientific and medical officer of ImmunityBio, holding a controlling equity stake. He is currently accused in a class-action lawsuit of overstating the capabilities of the company's drug, Anktiva.
Regulatory
Patrick Soon-Shiong: Patrick Soon-Shiong, ImmunityBio's Executive Chairman and Chief Scientific and Medical Officer, is accused of materially overstating Anktiva's capabilities, leading to the FDA warning and subsequent lawsuits.
ImmunityBio: ImmunityBio is the defendant in multiple securities class action lawsuits due to alleged misleading statements about its drug Anktiva, which caused its stock price to fall significantly. The company faces investigations and potential financial penalties.
Apr 02, 2026 · 132 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Patrick Soon-Shiong and ImmunityBio interact across events, view sentiment trends, and discover connected entities.
Open Dashboard